Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Editas Medicine, Inc.EDIT · Entity 5502 | Director | May 30, 2024 | June 03, 2024 |
| PAREXEL INTERNATIONAL CORPPRXL · Entity 172709 | Corp. VP & Interim CFO | December 07, 2016 | December 09, 2016 |
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | Director | January 02, 2026 | January 06, 2026 |
| Whitehawk Therapeutics, Inc.WHWK · Entity 6074 | Director | June 12, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Editas Medicine, Inc.
Report date May 30, 2024 · Filed June 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.17 · Expires 2034-05-29 | Direct | 25,000 |
Reported balance
After 2024-05-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-30 · Grant · Acquired 25,000 · Balance 25,000 F1: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025 |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025
PAREXEL INTERNATIONAL CORP
Report date December 07, 2016 · Filed December 09, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,468 |
Reported balance
After 2016-12-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2016-12-07 · Grant · Acquired 2,348 · Balance 8,468 F1: Shares of restricted stock awarded pursuant to PAREXEL International Corporation 2015 Stock Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of restricted stock awarded pursuant to PAREXEL International Corporation 2015 Stock Incentive Plan.
PTC THERAPEUTICS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,666 |
Ending reported balance
After 2026-01-05 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-01-02 · Grant · Acquired 4,000 · Balance 10,666 F1: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. Row 2 · 2026-01-05 · Exercise / conversion · Acquired 734 · Balance 11,400 F2: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. Row 3 · 2026-01-05 · Sale · Disposed 734 · Balance 10,666 F2: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.74 · Expires 2036-01-01 | Direct | 3,475 |
Reported balance
After 2026-01-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-02 · Grant · Acquired 3,475 · Balance 3,475 F3: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.54 · Expires 2035-01-02 | Direct | 0 |
Reported balance
After 2026-01-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-05 · Exercise / conversion · Disposed 734 · Balance 0 F2: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. F4: Currently exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027.
F2: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025.
F3: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026.
F4: Currently exercisable.
Whitehawk Therapeutics, Inc.
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16 · Expires 2036-06-12 | Direct | 38,040 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 38,040 · Balance 38,040 F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CONSTELLATION PHARMACEUTICALS INC
Report date July 15, 2021 · Filed July 19, 2021
Section 16 reporting ended · disclosed 2021-07-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.06 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-15 · Disposition to issuer · Disposed 60,000 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-07-15 · Disposition to issuer · Disposed 37,527 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.76 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-07-15 · Disposition to issuer · Disposed 73,428 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.04 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-07-15 · Disposition to issuer · Disposed 11,777 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-07-15 · Disposition to issuer · Disposed 17,666 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.61 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-07-15 · Disposition to issuer · Disposed 80,971 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.50 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-07-15 · Disposition to issuer · Disposed 66,950 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2021 Filed Jan 8, 2021 22:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 1,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-000465 · edgar.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,328 F1 · shares: Restricted stock units ("RSUs") granted on January 6, 2021 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 8, 2021 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 6, 2022. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 16:53 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 4,542 | $0.00 Strike: $6.61 | $0.00 |
DisclosureSEC source: 0001562180-20-007432 · primarydocument.xml · derivative · entry 5 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,971 Underlying: Common Stock · 4,542 shares Expires 2027-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on December 12, 2017. The shares underlying the option are scheduled to vest in equal quarterly installments through October 16, 2021. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 16:53 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 1,178 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0001562180-20-007432 · primarydocument.xml · derivative · entry 4 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,666 Underlying: Common Stock · 1,178 shares Expires 2028-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on March 6, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through March 6, 2022. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 16:53 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 5,720 | $35.11 | $200,805.18 |
DisclosureSEC source: 0001562180-20-007432 · primarydocument.xml · nonDerivative · entry 3 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 16:53 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 4,542 | $6.61 | $30,022.62 |
DisclosureSEC source: 0001562180-20-007432 · primarydocument.xml · nonDerivative · entry 2 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 16:53 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 1,178 | $7.60 | $8,952.80 |
DisclosureSEC source: 0001562180-20-007432 · primarydocument.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,028 | $33.02 Strike: $33.02 | $33,944.56 |
DisclosureSEC source: 0001179110-20-011991 · edgar.xml · derivative · entry 8 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 1,028 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 29, 2020. F2 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,028 | $33.02 | $33,944.56 |
DisclosureSEC source: 0001179110-20-011991 · edgar.xml · nonDerivative · entry 5 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 29, 2020. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 972 | $33.02 Strike: $33.02 | $32,095.44 |
DisclosureSEC source: 0001179110-20-011991 · edgar.xml · derivative · entry 7 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,028 Underlying: Common Stock · 972 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 29, 2020. F2 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $33.02 Strike: $33.02 | $33,020.00 |
DisclosureSEC source: 0001179110-20-011991 · edgar.xml · derivative · entry 6 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 1,000 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 29, 2020. F2 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 972 | $68.00 | $66,096.00 |
DisclosureSEC source: 0001179110-20-011991 · edgar.xml · nonDerivative · entry 4 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 29, 2020. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 972 | $33.02 | $32,095.44 |
DisclosureSEC source: 0001179110-20-011991 · edgar.xml · nonDerivative · entry 3 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 29, 2020. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,000 | $68.00 | $68,000.00 |
DisclosureSEC source: 0001179110-20-011991 · edgar.xml · nonDerivative · entry 2 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 29, 2020. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,000 | $33.02 | $33,020.00 |
DisclosureSEC source: 0001179110-20-011991 · edgar.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 29, 2020. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 18:50 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 589 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0001562180-20-004418 · primarydocument.xml · derivative · entry 5 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,844 Underlying: Common Stock · 589 shares Expires 2028-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on March 6, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through March 6, 2022. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 18:50 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 233 | $38.35 | $8,936.46 |
DisclosureSEC source: 0001562180-20-004418 · primarydocument.xml · nonDerivative · entry 4 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $38.12 to $38.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 18:50 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 144 | $37.67 | $5,423.88 |
DisclosureSEC source: 0001562180-20-004418 · primarydocument.xml · nonDerivative · entry 3 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $37.10 to $38.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 18:50 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 212 | $36.59 | $7,757.23 |
DisclosureSEC source: 0001562180-20-004418 · primarydocument.xml · nonDerivative · entry 2 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $36.06 to $37.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 18:50 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 589 | $7.60 | $4,476.40 |
DisclosureSEC source: 0001562180-20-004418 · primarydocument.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 12, 2020 21:41 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 1,520 | $0.00 Strike: $6.61 | $0.00 |
DisclosureSEC source: 0001562180-20-003563 · primarydocument.xml · derivative · entry 14 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,513 Underlying: Common Stock · 1,520 shares Expires 2027-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: This option was granted on December 12, 2017. The shares underlying the option are scheduled to vest in equal quarterly installments through October 16, 2021. Read SEC document |
| May 11, 2020 Filed May 12, 2020 21:41 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 1,178 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0001562180-20-003563 · primarydocument.xml · derivative · entry 13 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,433 Underlying: Common Stock · 1,178 shares Expires 2028-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: This option was granted on March 6, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through March 6, 2022. Read SEC document |
| May 11, 2020 Filed May 12, 2020 21:41 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 10,736 | $0.00 Strike: $8.76 | $0.00 |
DisclosureSEC source: 0001562180-20-003563 · primarydocument.xml · derivative · entry 12 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,428 Underlying: Common Stock · 10,736 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option was granted on March 7, 2019. The shares underlying the option are scheduled to vest in equal quarterly installments through March 7, 2023. Read SEC document |
| May 11, 2020 Filed May 12, 2020 21:41 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 2,628 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001562180-20-003563 · primarydocument.xml · derivative · entry 11 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,527 Underlying: Common Stock · 2,628 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on July 19, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through July 19, 2022. Read SEC document |
| May 11, 2020 Filed May 12, 2020 21:41 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 16,062 | $49.53 | $795,623.14 |
DisclosureSEC source: 0001562180-20-003563 · primarydocument.xml · nonDerivative · entry 8 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $49.50 to $49.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2020 Filed May 12, 2020 21:41 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 1,520 | $6.61 | $10,047.20 |
DisclosureSEC source: 0001562180-20-003563 · primarydocument.xml · nonDerivative · entry 7 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 12, 2020 21:41 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 1,178 | $7.60 | $8,952.80 |
DisclosureSEC source: 0001562180-20-003563 · primarydocument.xml · nonDerivative · entry 6 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 12, 2020 21:41 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 10,736 | $8.76 | $94,047.36 |
DisclosureSEC source: 0001562180-20-003563 · primarydocument.xml · nonDerivative · entry 5 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 12, 2020 21:41 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 2,628 | $11.50 | $30,222.00 |
DisclosureSEC source: 0001562180-20-003563 · primarydocument.xml · nonDerivative · entry 4 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,628 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:41 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 6,085 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001562180-20-003563 · primarydocument.xml · derivative · entry 10 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,557 Underlying: Common Stock · 6,085 shares Expires 2028-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on April 23, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through April 23, 2022. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:41 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 6,656 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001562180-20-003563 · primarydocument.xml · derivative · entry 9 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,155 Underlying: Common Stock · 6,656 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on July 19, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through July 19, 2022. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:41 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 12,741 | $49.53 | $631,055.36 |
DisclosureSEC source: 0001562180-20-003563 · primarydocument.xml · nonDerivative · entry 3 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $49.50 to $49.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:41 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 6,656 | $11.50 | $76,544.00 |
DisclosureSEC source: 0001562180-20-003563 · primarydocument.xml · nonDerivative · entry 2 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:41 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 6,085 | $8.04 | $48,923.40 |
DisclosureSEC source: 0001562180-20-003563 · primarydocument.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 17:53 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 760 | $0.00 Strike: $6.61 | $0.00 |
DisclosureSEC source: 0001562180-20-003063 · primarydocument.xml · derivative · entry 3 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,033 Underlying: Common Stock · 760 shares Expires 2027-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on December 11, 2017. The shares underlying the option are scheduled to vest in equal quarterly installments through October 16, 2021. Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 17:53 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 760 | $35.29 | $26,819.64 |
DisclosureSEC source: 0001562180-20-003063 · primarydocument.xml · nonDerivative · entry 2 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.21 to $35.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 17:53 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 760 | $6.61 | $5,023.60 |
DisclosureSEC source: 0001562180-20-003063 · primarydocument.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 14:31 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 1,225 | $0.00 Strike: $8.76 | $0.00 |
DisclosureSEC source: 0001562180-20-003027 · primarydocument.xml · derivative · entry 3 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,164 Underlying: Common Stock · 1,225 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on March 7, 2019. The shares underlying the option are scheduled to vest in equal quarterly installments through March 7, 2023. Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 14:31 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 1,225 | $35.20 | $43,122.70 |
DisclosureSEC source: 0001562180-20-003027 · primarydocument.xml · nonDerivative · entry 2 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 14:31 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 1,225 | $8.76 | $10,731.00 |
DisclosureSEC source: 0001562180-20-003027 · primarydocument.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 16:55 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 589 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0001562180-20-002990 · primarydocument.xml · derivative · entry 6 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,611 Underlying: Common Stock · 589 shares Expires 2028-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on March 6, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through March 6, 2022. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 16:55 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 111 | $0.00 Strike: $8.76 | $0.00 |
DisclosureSEC source: 0001562180-20-002990 · primarydocument.xml · derivative · entry 5 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,389 Underlying: Common Stock · 111 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on March 7, 2019. The shares underlying the option are scheduled to vest in equal quarterly installments through March 7, 2023. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 16:55 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 589 | $35.02 | $20,625.54 |
DisclosureSEC source: 0001562180-20-002990 · primarydocument.xml · nonDerivative · entry 4 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.075. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 16:55 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 589 | $7.60 | $4,476.40 |
DisclosureSEC source: 0001562180-20-002990 · primarydocument.xml · nonDerivative · entry 3 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 16:55 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 111 | $35.02 | $3,886.99 |
DisclosureSEC source: 0001562180-20-002990 · primarydocument.xml · nonDerivative · entry 2 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.075. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 16:55 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 111 | $8.76 | $972.36 |
DisclosureSEC source: 0001562180-20-002990 · primarydocument.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 16:58 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $36.06 | $0.00 |
DisclosureSEC source: 0000899243-20-004905 · doc4.xml · derivative · entry 1 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: This option was granted on February 14, 2020, and the shares underlying the option vest in equal quarterly installments through February 14, 2024, subject to continued service. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 17:09 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,521 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001562180-20-001251 · primarydocument.xml · derivative · entry 6 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,642 Underlying: Common Stock · 5,521 shares Expires 2028-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on April 23, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through April 23, 2022. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 17:09 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 5,521 | $35.06 | $193,539.21 |
DisclosureSEC source: 0001562180-20-001251 · primarydocument.xml · nonDerivative · entry 4 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 17:09 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 5,521 | $8.04 | $44,388.84 |
DisclosureSEC source: 0001562180-20-001251 · primarydocument.xml · nonDerivative · entry 3 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 17:09 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,103 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001562180-20-001251 · primarydocument.xml · derivative · entry 5 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,163 Underlying: Common Stock · 1,103 shares Expires 2028-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on April 23, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through April 23, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.